Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Just thought I would pass this along

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Mar 01, 2021 1:17pm

93 Views

Post# 32686409

RE:Just thought I would pass this along

Considering the sales of Trogarzo although improving would probably not coming close to the initial 4000 patients one has to wonder what would be the financial incentive for both companies to move on with a costly protocol for monthly administration of the drug.
I guess they both need to re access looking at how much of the difference the monthly administration's contribution to revenues would possibly be versus biweekly administration.

SPCEO1 wrote: I had either forgotten about these terms of the deal with Taimed or they were included in a revised agreement, probably the former. It is good to remember that $3 million will be owed in two equal annual installments once the IV Push begins sales. Given how long it has taken Taimed to get this done, a significant discount should be offered!

Also, I have not heard anything about a 1 month version of Trogarzo being studied recently, but the cost of studying it for TH could be quite extreme according to the contract.

Here are the details of the contract that I am referring to:

We also agreed to pay TaiMed a development milestone of US$3,000,000 upon the first commercial sale in the North American Territory of a bi-weekly intramuscular, subcutaneous or intravenous-push (either fast or slow) injection formulation. This milestone will be payable in two annual equal installments of US$1,500,000 each, with the first one being paid 30 days after the first sale of such new formulation in the North American Territory, while the second one will be paid 12 months thereafter.

We also agreed to pay TaiMed an additional development milestone as a result of the potential conduct by TaiMed of a phase III trial using Trogarzo® with a once every four-week intramuscular, subcutaneous or intravenous-push (either fast or slow) injection formulation. This development milestone would be equal to 50% of all costs associated with the development and approval of such new formulation, subject, however, to a maximum of US$50,000,000. TaiMed and we must agree on the amount of the milestone after taking into consideration the size of the market for this new formulation of Trogarzo® and the market exclusivity related thereto. The TaiMed Agreement contains a provision dealing with a disagreement between the parties on the determination of the amount of this development milestone. This development milestone would be paid quarterly, based on a percentage of net sales then generated by the sale of Trogarzo® using this new formulation, and would include a payment of interest on the principal.